Pfizer Brings Frequent Heartburn Relief Over-the-Counter with New Nexium® 24HR


NEW YORK – Pfizer Inc. (NYSE: PFE) today announced the introduction in the U.S. of over-the-counter (OTC) Nexium® 24HR, making The Purple Pill® available for the treatment of frequent heartburn (two or more days a week) in adults (18 years and older). Heartburn affects more than 60 million men and women in the United States […]

Pfizer cancels bid to purchase AstraZeneca


After many recent attempts to combine two companies into one, Pfizer decides to call it quits when it comes to purchasing AstraZenaca. Following AstraZenaca’s board’s rejection of the roughly $120 billion offer, Pfizer announced that it does not intend to make any more offers for AstraZeneca. “We continue to believe that our final proposal was […]

Over-The-Counter Nexium


Pfizer Inc. (NYSE: PFE) today announced that it has entered into an agreement with AstraZeneca for the over-the-counter (OTC) rights for NEXIUM (esomeprazole magnesium), a leading prescription drug currently approved to treat the symptoms of gastroesophageal reflux disease (GERD). Under the terms of the agreement, Pfizer will acquire the exclusive global rights to market NEXIUM […]

Pfizer Issues Statement On Voluntary Recall


Pfizer Inc. today issued the following statement regarding the voluntary recall of Lo/Ovral®-28 (norgestrel and ethinyl estradiol): “Upon discovery of the issue, we took corrective action and notified the FDA.” “We have announced a voluntary recall of Lo/Ovral®-28 (norgestrel and ethinyl estradiol) and Norgestrel and Ethinyl Estradiol Tablets (generic) birth control pills in the United […]

Pfizer Completes Acquisition of Excaliard

Pfizer Inc. (NYSE: PFE) announced today that it has completed its acquisition of Excaliard Pharmaceuticals, Inc., a privately owned biopharmaceutical company focused on developing novel drugs for the treatment of skin fibrosis, more commonly referred to as skin scarring. “It is imperative at Pfizer that we continue to develop new and innovative treatments to address […]

FDA Accepts ELIQUIS® (apixaban) New Drug Application


Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a New Drug Application (NDA) for ELIQUIS® (apixaban), an investigational compound for the prevention of stroke and systemic embolism in patients with atrial fibrillation. The FDA accepted the filing and assigned […]

Pfizer to Acquire Excaliard Pharmaceuticals


Pfizer Inc. (NYSE: PFE) and Excaliard Pharmaceuticals, Inc. announced today that they have entered into a definitive agreement under which Pfizer will acquire Excaliard, a privately owned biopharmaceutical company focused on developing novel drugs for the treatment of skin fibrosis, more commonly referred to as skin scarring. The acquisition is expected to close before the […]

Pfizer Wins Corporate Citizenship Award For Global Health Partnerships Program

Pfizer Inc. today announced that it has received the 2011 Business Civic Leadership Center’s Corporate Citizenship Award in the Best International Ambassador category for Pfizer’s Global Health Partnerships program. The “Citizens” Awards honor excellence in corporate citizenship and civic leadership for initiatives in both the United States and across the world. “Pfizer is proud to […]

First Therapy Approved in the European Union for the Rare and Fatal Neurodegenerative Disease Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP)

Pfizer announced today that the European Commission has approved Vyndaqel® (tafamidis) for the treatment of Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP) in adult patients with stage 1 symptomatic polyneuropathy. TTR-FAP is a rare, progressive and fatal neurodegenerative disease that affects approximately 8,000 patients worldwide. 1,2,3 “Today marks a real breakthrough for patients in the EU living […]

The Advil® Congestion Relief Project Hits the Road to Relieve Congestion in Communities


Pfizer Consumer Healthcare, the makers of Advil® Congestion Relief, yesterday, kicked off a nationwide effort to make a difference in communities. The cold and flu brand is putting a twist on its tagline – “The Right Relief for the Real Problem,” and providing literal relief in congested places across the US. In its first relief […]